Medicines Co. (MDCO): A High Bar Could Lead to Ph3 Trials Despite Ending Early - Jefferies

August 31, 2016 8:35 AM EDT
Get Alerts MDCO Hot Sheet
Price: $36.33 -0.49%

Rating Summary:
    14 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MDCO Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of The Medicines Company (NASDAQ: MDCO) after reviewing the first 40 pts of the MILANO-PILOT investigating the MDCO-216 which showed that the pre-defined, upper stat boundary for efficacy was not met, and the summary data at this time were “inconclusive.” MDCO had not disclosed the bar for stopping the trial early, but the analyst suspects that it was a high bar.

He is awaiting the final analysis at AHA in Nov, and if it can show a >1% decrease in % atheroma volume at wk 5, it could support moving forward to PIII trials. There is no change to the price target of $43.

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $40.14 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Jefferies & Co

Add Your Comment